Boehringer Ingelheim: Hepatitis C trials
The registry lists 10 Hepatitis C studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 4Phase 2 2Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver CirrhosisCompletedNCT01909778Phase 1Results posted
- Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine CapsulesCompletedNCT01704846Phase 1Results posted
- Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/NaloxoneCompletedNCT01637922Phase 1Results posted
- Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal ImpairmentCompletedNCT01580306Phase 1Results posted
- Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination TrialCompletedNCT01579474Phase 3Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedNCT01343888Phase 3Results posted
- A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
- Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedNCT00984620Phase 2Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) PatientsCompletedNCT00947349Phase 2Results posted